litlas
Log inCreate account

Daniel J. Hicklin

Active 1990–2023

117
Papers
50,512
Citations
102
h-index
117
i10-index

Citations

Citations per year for Daniel J. Hicklin1926: 1 citations1951: 1 citations1984: 4 citations1990: 3 citations1991: 7 citations1992: 8 citations1993: 13 citations1994: 18 citations1995: 7 citations1996: 16 citations1997: 13 citations1998: 20 citations1999: 47 citations2000: 128 citations2001: 216 citations2002: 438 citations2003: 667 citations2004: 727 citations2005: 825 citations2006: 983 citations2007: 914 citations2008: 956 citations2009: 924 citations2010: 883 citations2011: 812 citations2012: 645 citations2013: 598 citations2014: 486 citations2015: 450 citations2016: 438 citations2017: 393 citations2018: 328 citations2019: 967 citations2020: 960 citations2021: 830 citations2022: 555 citations2023: 421 citations2024: 586 citations2025: 225 citations2026: 5 citations1927–1950: no citations, so these years are not shown1952–1983: no citations, so these years are not shown1985–1989: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,923 citing papers, 33.6% of this breakdownChina: 1,607 citing papers, 9.1% of this breakdownGermany: 1,041 citing papers, 5.9% of this breakdownUnited Kingdom: 970 citing papers, 5.5% of this breakdownItaly: 903 citing papers, 5.1% of this breakdownJapan: 725 citing papers, 4.1% of this breakdownCanada: 596 citing papers, 3.4% of this breakdownFrance: 589 citing papers, 3.3% of this breakdownSwitzerland: 465 citing papers, 2.6% of this breakdownSpain: 408 citing papers, 2.3% of this breakdownAustralia: 381 citing papers, 2.2% of this breakdownNetherlands: 381 citing papers, 2.2% of this breakdown
0%33.6%Other 20.7%

Institutions

Fields

  • Medicine45.3%
  • Biochemistry, Genetics and Molecular Biology39.5%
  • Immunology and Microbiology8.1%
  • Neuroscience1.9%
  • Materials Science1.5%
  • Engineering1.5%
  • Other2.2%

Topics

  • Angiogenesis and VEGF in Cancer8.7%
  • Cancer, Hypoxia, and Metabolism4.2%
  • Cancer Cells and Metastasis2.9%
  • PI3K/AKT/mTOR signaling in cancer2.2%
  • Immunotherapy and Immune Responses2%
  • Immune cells in cancer2%
  • Other78%

Coauthors

All papers

Open in search
  1. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

    Authors: Rosandra N. Kaplan, Rebecca D. Riba, Stergios Zacharoulis, Anna H. Bramley, Loı̈c Vincent, Carla Costa, Daniel D. MacDonald, David Jin, Koji Shido, Scott Kerns, Zhenping Zhu, Daniel J. Hicklin, Yan Wu, Jeffrey L. Port, Nasser K. Altorki, Elisa Port, Davide Ruggero, Sergey V. Shmelkov, Kristian K. Jensen, Shahin Rafii, David Lyden - Nature 2005 cited by 3,260

  2. Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis

    Authors: Daniel J. Hicklin, Lee M. Ellis - Journal of Clinical Oncology 2004 cited by 3,008

  3. Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose

    Authors: Christine H. Chung, Beloo Mirakhur, Emily Chan, Quynh‐Thu Le, Jordan Berlin, Michael A. Morse, Barbara A. Murphy, Shama M. Satinover, Jacob D. Hosen, David Mauro, Robbert J.C. Slebos, Qinwei Zhou, Diane R. Gold, Tina Hatley, Daniel J. Hicklin, Thomas A.E. Platts‐Mills - New England Journal of Medicine 2008 cited by 1,483

  4. Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors

    Authors: Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian J. Long, Jenny Liu, Edward DiNunzio, William T. Windsor, Rumin Zhang, Shuxia Zhao, Minilik Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald W. Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul T. Kirschmeier, W. Robert Bishop, Daniel J. Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen E. Fawell, Ahmed A. Samatar - Cancer Discovery 2013 cited by 685

  5. mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

    Authors: Kathryn O’Reilly, F. Rojo, Qing‐Bai She, David B. Solit, Gordon B. Mills, Debra L. Smith, Heidi A. Lane, Francesco Hofmann, Daniel J. Hicklin, Dale L. Ludwig, José Baselga, Neal Rosen - Cancer Research 2006 cited by 2,552

  6. VEGF-targeted therapy: mechanisms of anti-tumour activity

    Authors: Lee M. Ellis, Daniel J. Hicklin - Nature reviews. Cancer 2008 cited by 1,668

  7. Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors

    Authors: Ricky T. Tong, Yves Boucher, Sergey V. Kozin, Frank Winkler, Daniel J. Hicklin, Rakesh K. Jain - Cancer Research 2004 cited by 1,186

  8. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

    Authors: Oriol Casanovas, Daniel J. Hicklin, Gabriele Bergers, Douglas Hanahan - Cancer Cell 2005 cited by 1,609

  9. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions

    Authors: Peter Carmeliet, Lieve Moons, Aernout Luttun, Valeria Vincenti, Veerle Compernolle, Maria De Mol, Yan Wu, Françoise Bono, Laetitia Devy, Heike Beck, Dimitri Scholz, Till Acker, Tina Di Palma, Mieke Dewerchin, Agnès Noël, Ingeborg Stalmans, Adriano Barra, S. Blacher, Thierry VandenDriessche, Annica Pontén, Ulf Eriksson, Karl H. Plate, Jean‐Michel Foidart, Wolfgang Schäper, D. Stephen Charnock‐Jones, Daniel J. Hicklin, Jean‐Marc Herbert, D Collen, M. Graziella Persico - Nature Medicine 2001 cited by 1,667

  10. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation

    Authors: Frank Winkler, Sergey V. Kozin, Ricky T. Tong, Sung‐Suk Chae, Michael F. Booth, Igor Garkavtsev, Lei Xu, Daniel J. Hicklin, Dai Fukumura, Emmanuelle di Tomaso, Lance L. Munn, Rakesh K. Jain - Cancer Cell 2004 cited by 1,176

  11. Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression

    Authors: Christopher J. Nirschl, Heather R. Brodkin, Daniel J. Hicklin, Nesreen Ismail, Kristin Morris, Cynthia Seidel-Dugan, Philipp Steiner, Zoe Steuert, Jenna M. Sullivan, Ethika Tyagi, William M. Winston, Andres Salmeron - Cancer Immunology Research 2022 cited by 57

  12. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiationRole of oxygenation, angiopoietin-1, and matrix metalloproteinases

    Authors: F.K. Winkler, Sergey V. Kozin, R. Tong, Su-Kyoung Chae, Megan Booth, Igor Garkavtsev, Li Xu, Daniel J. Hicklin, Dai Fukumura, Emmanuelle DiTomaso - Cancer Cell 2004 cited by 679

  13. Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance

    Authors: Francesco M. Marincola, Elizabeth M. Jaffee, Daniel J. Hicklin, S Ferrone - Advances in immunology 1999 cited by 1,167

  14. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors

    Authors: Mario Peichev, Afzal J. Naiyer, Daniel Peixoto Pereira, Zhenping Zhu, William J. Lane, Mathew Williams, Mehmet Oz, Daniel J. Hicklin, Larry Witte, Malcolm A.S. Moore, Shahin Rafii - Blood 2000 cited by 2,261

  15. Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology

    Authors: Lee M. Ellis, Daniel J. Hicklin - Clinical Cancer Research 2009 cited by 250

  16. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

    Authors: Giannoula Klement, Sylvain Baruchel, Janusz Rak, Shan Man, Katherine Clark, Daniel J. Hicklin, Peter Böhlen, Robert S. Kerbel - Journal of Clinical Investigation 2000 cited by 1,175

  17. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration

    Authors: Bert Oosthuyse, Lieve Moons, Erik Storkebaum, Heike Beck, Dieter Nuyens, Koen Brusselmans, Jo Van Dorpe, Peter W. Hellings, M. Gorselink, Stéphane Heymans, Gregor Theilmeier, Mieke Dewerchin, Vincent Laudenbach, P. Vermylen, Harold Raat, Till Acker, V. Vleminckx, Ludo Van Den Bosch, Neil R. Cashman, Hajime Fujisawa, Maarten R. Drost, Raf Sciot, Frans Bruyninckx, Daniel J. Hicklin, Can İnce, Pierre Gressèns, Florea Lupu, Karl H. Plate, Wim Robberecht, Jean‐Marc Herbert, Désiré Collen, Peter Carmeliet - Nature Genetics 2001 cited by 1,010

  18. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1

    Authors: Monica Autiero, Johannes Waltenberger, Didier Communi, Andrea Kranz, Lieve Moons, Diether Lambrechts, Jens Krøll, Stéphane Plaisance, Maria De Mol, Françoise Bono, Stefanie Kliche, Guido Fellbrich, Kurt Ballmer‐Hofer, Domenico Maglione, Ulrike Mayr-Beyrle, Mieke Dewerchin, Saskia Dombrowski, Danica Stanimirovic, Paul Van Hummelen, Christoph Dehio, Daniel J. Hicklin, Graziella Persico, Jean‐Marc Herbert, David Communi, Masabumi Shibuya, D Collen, Edward M. Conway, Peter Carmeliet - Nature Medicine 2003 cited by 766

  19. Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

    Authors: David Lyden, Koichi Hattori, Sérgio Dias, Carla Costa, Pamela Blaikie, Linda Butros, Amy Chadburn, Beate Heissig, Willy Marks, Larry Witte, Yan Wu, Daniel J. Hicklin, Zhenping Zhu, Neil R. Hackett, Ronald G. Crystal, Malcolm A.S. Moore, Katherine A. Hajjar, Katia Manova, Robert Benezra, Shahin Rafii - Nature Medicine 2001 cited by 1,852

  20. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1

    Authors: Aernout Luttun, Marc Tjwa, Lieve Moons, Yan Wu, Anne Angelillo‐Scherrer, Fang Liao, Janice A. Nagy, Andrea T. Hooper, Josef Priller, Bert De Klerck, Veerle Compernolle, Evis Daci, Peter Böhlen, Mieke Dewerchin, Jean-Marc Herbert, Roy A. Fava, Patrick Matthys, Geert Carmeliet, D Collen, Harold F. Dvorak, Daniel J. Hicklin, Peter Carmeliet - Nature Medicine 2002 cited by 1,062

  21. Vascular Endothelial Growth Factor Receptor 3 Is Involved in Tumor Angiogenesis and Growth

    Authors: Pirjo Laakkonen, Marika Waltari, Tanja Holopainen, Takashi Takahashi, Bronislaw Pytowski, Philipp Steiner, Daniel J. Hicklin, Kris Persaud, James R. Tonra, Larry Witte, Kari Alitalo - Cancer Research 2007 cited by 241

  22. Vascular Endothelial Growth Factor Receptor-1 Activation Mediates Epithelial to Mesenchymal Transition in Human Pancreatic Carcinoma Cells

    Authors: Anthony D. Yang, E. Ramsay Camp, Fan Fan, Lanlan Shen, Michael J. Gray, Wenbiao Liu, Ray Somcio, Todd W. Bauer, Yan Wu, Daniel J. Hicklin, Lee M. Ellis - Cancer Research 2006 cited by 286

  23. A Comparative Analysis of Low-Dose Metronomic Cyclophosphamide Reveals Absent or Low-Grade Toxicity on Tissues Highly Sensitive to the Toxic Effects of Maximum Tolerated Dose Regimens

    Authors: Urban Emmenegger, Shan Man, Yuval Shaked, Giulio Francia, John Wong, Daniel J. Hicklin, Robert S. Kerbel - Cancer Research 2004 cited by 135

  24. Vascular Trauma Induces Rapid but Transient Mobilization of VEGFR2 + AC133 + Endothelial Precursor Cells

    Authors: Muhammad Gill, Sérgio Dias, Koichi Hattori, Mary Rivera, Daniel J. Hicklin, Larry Witte, Leonard N. Girardi, Roger W. Yurt, Harvey N. Himel, Shahin Rafii - Circulation Research 2001 cited by 799